Lipophilic antioxidants in neurodegenerative diseases

Publication date: October 2018Source: Clinica Chimica Acta, Volume 485Author(s): Kuo-Hsuan Chang, Mei-Ling Cheng, Mu-Chun Chiang, Chiung-Mei ChenAbstractOxidative stress is commonly involved in the pathogenesis of various neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. Therefore, lipophilic antioxidants, such as vitamin A, carotinoids, vitamin E, coenzyme Q10, docosahexaenoic acid and eicosapentaenoic acid, have received increasing attention as therapeutic and preventive intervention for neurodegenerative diseases. Although difficulties exist with clinical studies due to the nature of the long-standing progression of neurodegenerative diseases, findings in cell and animal models, as well as biomarker studies have implied a relationship between lipophilic antioxidants and neurodegeneration. By reviewing current findings and their implication in neurodegenerative diseases, we conclude that although none of these lipophilic antioxidants have yet provided clear-cut clinical evidence toward beneficial effects in neurodegenerative diseases, they could demonstrate neuroprotection in cellular and/or animal studies. Results from future multidisciplinary studies with optimization of factors including drug dosage, delivery route and chemical structure may provide us with novel treatments for neurodegenerative diseases using lipophilic antioxidants.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research

Related Links:

ron;imić G Abstract Two clinically distinct diseases, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), have recently been classified as two extremes of the FTD/ALS spectrum. The neuropathological correlate of FTD is frontotemporal lobar degeneration (FTLD), characterized by tau-, TDP-43-, and FUS-immunoreactive neuronal inclusions. An earlier discovery that a hexanucleotide repeat expansion mutation in chromosome 9 open reading frame 72 (C9orf72) gene causes ALS and FTD established a special subtype of ALS and FTLD with TDP-43 pathology (C9FTD/ALS). Normal individuals carry 2-10 hexanucleoti...
Source: Behavioural Neurology - Category: Neurology Authors: Tags: Behav Neurol Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
AbstractSpinal cord injury (SCI) is a devastating condition that has few treatment options. Riluzole, a sodium channel blocker used to treat amyotrophic lateral sclerosis, has been initially trialed in human SCI. We performed a systematic review to critically assess the efficacy of riluzole in locomotor recovery and damage extension in SCI rat models, and the potential for clinical translation. PubMed, Embase, Cochrane Library, and Chinese databases were searched from their inception date to March 2018. Two reviewers independently selected animal studies that evaluated neurological recovery and lesion area following riluzo...
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Review Source Type: research
CONCLUSIONS: Ultrasound-guided botulinum toxin injections into the parotid and submandibular glands seem to be a safe and effective therapy for the treatment of drooling. Further long-term prospective studies with varying doses are warranted. PMID: 30772963 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
AbstractHereditary spastic paraplegias (HSPs) are clinically and genetically heterogeneous neurodegenerative disorders. Numerous genes linked to HSPs, overlapping phenotypes between HSP subtypes and other neurodegenerative disorders and the HSPs ’ dual mode of inheritance (both dominant and recessive) make the genetic diagnosis of HSPs complex and difficult. Out of the original HSP cohort comprising 306 index cases (familial and isolated) who had been tested according to “traditional workflow/guidelines” by Multiplex Ligation-dependen t Probe Amplification (MLPA) and Sanger sequencing, 30 unrelated patien...
Source: Neurogenetics - Category: Genetics & Stem Cells Source Type: research
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease without effective treatment. The receptor for advanced glycation end products (RAGE) and the toll-like receptor ...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Condition:   Amyotrophic Lateral Sclerosis Intervention:   Drug: Gold Nanocrystals Sponsors:   Clene Nanomedicine;   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
Corrigendum to "Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis" [Brain Research Bulletin 140 (2018) 318-333]. Brain Res Bull. 2019 Mar;146:327 Authors: Fogarty MJ PMID: 30770039 [PubMed - in process]
Source: Brain Research Bulletin - Category: Neurology Authors: Tags: Brain Res Bull Source Type: research
More News: ALS | Brain | Chemistry | Neurology | Study | Vitamin A | Vitamin E | Vitamins